{"id":6651,"date":"2024-11-21T16:01:35","date_gmt":"2024-11-21T15:01:35","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6651"},"modified":"2025-04-28T21:26:54","modified_gmt":"2025-04-28T19:26:54","slug":"saffron-104-a-phase-ib-ii-study-of-sitravatinib-alone-or-with-tislelizumab-in-advanced-hepatocellular-carcinoma-and-gastric-cancer-gastroesophageal-junction-cancer","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/saffron-104-a-phase-ib-ii-study-of-sitravatinib-alone-or-with-tislelizumab-in-advanced-hepatocellular-carcinoma-and-gastric-cancer-gastroesophageal-junction-cancer\/","title":{"rendered":"SAFFRON-104: a phase Ib\/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer\/gastroesophageal junction cancer\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6651","publication","type-publication","status-publish","hentry","disease_state-gastic-gastroesophageal-junction-cancer","disease_state-hepatocellular-carcinoma","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6651"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}